ArticleACR open rheumatology2025
Effects of Audio-Guided Imagery on Raynaud Phenomenon in Connective Tissue Disease.
Article in ACR open rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo assess the physical, emotional, and mental impact of regular audio-guided imagery (AGI) in patients with connective tissue disease (CTD)-associated Raynaud phenomenon (RP).
methodsSixteen adult patients with CTD-associated RP were enrolled in an open-label, single-arm, eight-week intervention with daily AGI at a single center. Patients completed surveys, including assessment of RP severity, depression/anxiety, and quality of life at baseline and the end of eight weeks.
resultsStudy participants demonstrated significant improvement in all patient reported outcomes, except Generalized Anxiety Disorder 7, which showed improvement but was not statistically significant. This eight-week intervention shows that patients with CTD-associated RP had less severe RP episodes, as well as improved quality of life and depressive symptoms.
conclusionAGI significantly improved several domains of health, including physical, emotional, and mental, in patients with CTD-associated RP who otherwise more commonly struggle with more RP attacks, lower quality of life, and depression. AGI is a low-cost, low-risk, and convenient therapy for CTD-associated RP. A larger study studying the effects of this intervention is indicated.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.